甘李药业：博凡格鲁肽注射液还在临床中，商业化产生的具体收益，取决于产品后续研发、注册等

Core Viewpoint - Ganli Pharmaceutical has granted exclusive rights to develop and commercialize the injection of Bofan Glutide in Latin America, including key countries like Mexico and Brazil, to PC, marking a new commercial strategy for Ganli's innovative drug in the region [1] Group 1 - Ganli Pharmaceutical confirmed that the Bofan Glutide injection is still in clinical trials, and the specific revenue from commercialization will depend on the success and progress of subsequent research, registration, and market introduction [1] - The company will fulfill its information disclosure obligations regarding future drug trial arrangements and significant commercial progress [1]